Re-radiation and Chidamide for Recurrent Head and Neck Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests combining re-radiation (radiation therapy given a second time) with a drug called chidamide to treat head and neck cancer that has come back after previous radiation. The goal is to see if this combination can help patients whose cancer cannot be removed by surgery or who cannot have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old with at least 3 months expected survival
- Diagnosed head and neck squamous cell carcinoma that came back in the same area after prior radiation (at least 6 months after radiation ended)
- Cancer cannot be surgically removed, or you chose not to have surgery, or you are medically unable to have surgery
- Good overall health and ability to care for yourself (ECOG score 0–1)
- Normal blood counts, liver, kidney, and heart function on recent lab tests
- No cancer spread to distant organs, no prior HDAC inhibitor treatment, and no severe heart problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This trial tests whether combining radiation therapy with immunotherapy works better than immunotherapy alone for advanced head and neck cancer that hasn't been treated before. The goal is to help your body's immune system fight the cancer more effectively.
This trial tests a type of radiation called carbon-ion re-irradiation for people whose head and neck cancer has come back or grown again after earlier radiation. It may help control the cancer after certain surgeries, but it also requires specific safety conditions about timing, prior treatment areas, and overall health.
This study tests whether adding the drug camonsertib to radiation therapy can help people whose head and neck cancer has come back in a spot that was already treated with radiation. Camonsertib is an experimental drug that may help radiation work better.
Hear when a new Head and Neck Squamous Cell Carcinoma HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.